TABLE 3.

Antibody concentrations and OPA titers in selected sera from Finnish children vaccinated with 7vCRM, 7vOMPC, or 11Pn-PD at the ages of 2, 4, 6, and 12 to 15 monthsa

Vaccine (n)b22F-ELISAOPA assay
% of samples with antibody concns of ≥0.35 μg/ml (95% CI)GMC (μg/ml) (95% CI)% of samples with OPA titers of ≥8 (95% CI)OPA GMT (95% CI)
19F19A19F19A19F19A19F19A
7vCRM (29-30)100 (88-100)72 (53-87)9.3 (7.2-11.9)0.7 (0.5-1.0)100 (88-100)10 (2-27)55.7 (39.9-77.8)4.9 (3.8-6.3)
7vOMPC (29-30)100 (88-100)62 (42-79)9.3 (7.5-11.6)0.4 (0.3-0.6)87 (69-96)20 (8-39)35 (22-55)4.9 (4.2-5.8)
11Pn-PD (25-26)100 (86-100)44 (24-65)11.9 (8.8-16.0)0.4 (0.3-0.7)100 (86-100)68 (47-85)99.6 (74.6-133.3)14.6 (9.0-24.1)
  • a Samples were obtained from children 1 month after the third or the fourth PCV dose, with a 2:1 ratio between the number of samples taken after three and four doses. GMC, geometric mean concentration; GMT, geometric mean titer.

  • b n, number of serum samples for which results were available.